Posted: September 4, 2014 at 8:44 am
Dr Adam Miller Talks Modern Medicine
Dr. Miller has experience as an oral and facial cosmetic surgeon, sleep apnea specialist, skin cancer expert, and is stem cell/ regenerative medicine and Age Management certified. He helped...
By: adam miller
Read more:
Dr Adam Miller Talks Modern Medicine - Video
Posted: September 4, 2014 at 8:41 am
La Jolla, CA (PRWEB) September 03, 2014
A new study, published on Aug. 8th, 2014 in Stem Cells Translational Medicine, has shown the positive effect stem cell therapy has had on a group of patients only 6 months after their treatment. Researchers observed significant improvements in disease-related complications in each of the 5 patients included in the study. Post-treatment brain scans of each patient revealed that stroke-related damage was reduced over time. Further, at six-month follow-ups patients demonstrated improvements in standard measures of stroke-related disability and impairment.
Researchers are being cautiously optimistic when considering these results. Similar improvements are often seen in stroke patients as part of the normal recovery process and state that more thorough studies will need to be completed. Nonetheless, the findings are absolutely astounding as the five patients included in this study suffered severe strokes. Four out of five of the patients had the most serious type of stroke. Normally only 4% of these patients survive and are able to live independently after six months of a stroke occurrence.
Clinical studies for stem cell treatment are currently being offered by StemGenex to patients diagnosed with Stroke and other degenerative neurological diseases. Innovation is truly a driving force for StemGenex. Stroke Patients who receive stem cell treatment through StemGenex receive multiple therapeutic modalities they simply cannot find elsewhere under one roof, said Jeremiah McDole, Director of Scientific Research and Development at StemGenex. Offering targeted therapies that deliver stem cells past the blood brain barrier is essential to providing effective treatment for patients with neurological disorders.
StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple Sclerosis, Parkinsons Alzheimers disease, and others. Rita Alexander, founder of StemGenex and the companys first stem cell patient, insists that all patients be treated like they are one of our loved ones. Hope, compassion, and the relentless pursuit for an end to these diseases are the primary focus.
To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com
Posted: September 4, 2014 at 1:51 am
Dubai: Stem cells harvested from the umbilical cord blood can save lives.
Of the 3,377 stem cells collected so far at the Dubai Cord Blood and Research Centre (DCRC), nine have been used for life-saving transplants in children in cases of leukaemia and other blood diseases.
Advocating the importance of public donation of cord blood stem cells to help form a substantial registry of stem cells for the UAE, Kareema Salim Al Arrayed, head of DCRC, said: Since the inception of this centre in 2006, we have seen an increase in the awareness levels about cord blood banking and this has directly attributed to an increase in the number of people who save their cord blood at our cord blood bank. However, we need to raise awareness that cord blood stem cells can be donated. Presently, more than 80 diseases can be cured with the help of stem cells and this includes leukaemia, and treatment of genetic disorders such as thalassaemia.
She added: The DCRC encourages families to donate cord blood stem cells so that we have a strong UAE public registry to help people in need. Stem cells are the future of medicine and public banking is a trend that is catching on globally due to the several diseases stem cells can cure.
Many women today opt for cord blood collection at the time of birth and DCRC provides pregnant women and their families a guided tour of the centre and its facilities to engender their interest in preserving stem cells for their families or for the purpose of donation.
The DCRC was established in 2006 and the prime objective of the centre is to retrieve a newborns umbilical cord blood at birth and extract the haemopoietic stem cells and carry out its cryopreservation. The DCRC spokesperson explained that the umbilical cord blood is what remains in the placenta following birth. The placenta is the temporary organ that transfers oxygen and nutrients to the baby via the umbilical cord while in the mothers uterus. Until recently, in most cases, the umbilical cord and the placenta were discarded after birth. In the last decade, scientists and researchers have discovered that the umbilical cord blood could supply stem cells, the hidden treasure of life. These stem cells can be used to replace blood-forming cells in a person being treated for cancer or other life-threatening diseases such as haemoglobinopathies, leukaemia, immune system deficiencies and numerous genetic diseases and it holds out hope for incurable diseases.
Visit link:
Cord blood stem cells a life saviour
Posted: September 3, 2014 at 9:41 pm
Can Extended Breastfeeding stem cells Cure Autism 2014
By: Breast Feeding Official
Visit link:
Can Extended Breastfeeding stem cells Cure Autism 2014 - Video
Posted: September 3, 2014 at 3:45 am
Sep 01, 2014 The biobank comprises three cryotanks, equipped with cooled protective hoods, and a transfer station from which the sample containers are transported via a rail system. There is enough space for approximately 60,000 samples. Credit: Fraunhofer IBMT
For the development of new drugs it is crucial to work with stem cells, as these allow scientists to study the effects of new active pharmaceutical ingredients. But it has always been difficult to derive enough stem cells of the right quality and in the right timeframe. A central biobank is about to remedy the situation.
Human stem cells allow scientists to assess how patients are likely to respond to new drugs and to examine how illnesses come about. For a few years now, it has been possible to take tissue samples from adults and use reverse programming to artificially produce stem cells, which have the potential to create any kind of cell found in the human body. Before this discovery, pharmaceutical researchers had to use adult stem cells or primary cells, which have a more limited potential. Another option is to use stem cells derived from human embryos, but quite apart from the ethical considerations these cells are available only in limited diversity. The new technique makes it possible for instance to reprogram adult skin or blood cells so that they behave in a similar way to embryonic stem cells and can become any type of cell. "These are known as induced pluripotent stem cells, or iPS cells for short," says Dr. Julia Neubauer from the Fraunhofer Institute for Biomedical Engineering IBMT in St. Ingbert, Germany. Although an increasing number of local biobanks have emerged in recent years, none of them fulfills the requirements of the pharmaceutical industry and research institutions. What is needed is a supply of 'ready-to-use' stem cells, which means large numbers of consistently characterized, systematically catalogued cells of suitable quality.
At the beginning of 2014, the IBMT teamed up with 26 industry and research partners to launch a project aimed at establishing a central biobank the European Bank for induced pluripotent Stem Cells (EBiSC) to generate iPS cells from patients with specific diseases or genetic mutations (http://ebisc.org/). Six months into the project and the first cells are available for use in the development of new drugs. By its three-year mark, it is hoped the project will be in a position to offer over 1000 defined and characterized cell lines comprising a hundred million cells. Such quantities are needed because a single drug screening involves testing several million cells. The main biobank facility is being built in the English city of Cambridge and an identical "mirror site" will be set up at the IBMT's Sulzbach location in Germany.
Gently freezing cells
The IBMT was brought on board for EBiSC by virtue of the comprehensive expertise it gained through participation in the EU's "Hyperlab" and "CRYSTAL" projects. For EBiSC, IBMT scientists are responsible for freezing the cells and for automating cell cultivation and the biobank itself. For an efficient long-term storage of functional stem cells, they have to be cooled down to temperatures of below 130 degrees Celsius in a controlled way. The scientists have to prepare the cells so they can survive the cold shock of nitrogen gas. The IBMT has, for instance, developed technologies that allow cells to be frozen in an extremely gentle way. "Cells don't like being removed from the surface they are grown on, but that's what people used to do in order to freeze them. Our method allows the cells to stay adherent," explains Neubauer.
Just as with foodstuffs, stem cells depend on an unbroken cold chain to preserve their functionality and viability. The scientists store the cells in special containers or cryotanks each measuring one by two meters. To remove a particular sample, the scientists have to open the cryotank. The problem is that this exposes all the other samples to warmer ambient air, causing them to begin to thaw out. "It's just like when you go to your refrigerator at home it's not a good idea to leave the door open too long," says Neubauer. She and her colleagues at the IBMT and industry partner Askion GmbH have together developed a stem cell biobank complete with protective hoods that protect the other samples whenever the cryotank is opened. In addition to maintaining the temperature, the hoods help keep another key shelf-life criterion, humidity, at a constant level.
Flawless freezing is important, but it is just as important to automate the whole process. "That not only guarantees consistency, it's what makes it possible to provide large quantities of cells of the required quality in the first place," says Neubauer. And the scientists' cooling process already boasts a finished technology. In their automated biobank, each cell sample is labelled with barcodes to allow them to be tracked. The samples travel along a conveyor belt to the individual cyrotanks, and a computer monitors the entire freezing and storage process.
Now the scientists are working on automating cell cultivation or the multiplying of the cells. There are essentially two possible approaches. One is to use robots that translate each preparation step into a mechanical one. The other is to use stirred bioreactors that provide free-moving cells with the ideal supply of nutrients and oxygen. Both technologies feature in the IBMT's portfolio. "By the time the project is completed, we'll know which is the better method for what we're trying to do," says Neubauer.
Explore further: Animal-free reprogramming of adult cells improves safety
Continue reading here:
Central biobank for drug research
Posted: September 3, 2014 at 3:45 am
Researchers have recently found a method to expand blood stem cells that could lead to new and better cancer treatment, it has been reported.
Scientists from the University Of Colorado School Of Medicine have reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications that extend beyond cancer, including treatments for inborn immunodeficiency and metabolic conditions and autoimmune diseases.
Researchers from the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and Taiga Biotechnologies, Inc. said they have uncovered the keys to the molecular code that appear to regulate the ability of blood stem cells to reproduce and retain their stem-like characteristics.
The team developed protein products that can be directly administered to blood stem cells to encourage them to multiply without permanent genetic modifications. The technology described in the article has worked with blood stem cells obtained from cord blood, adult bone marrow or peripheral blood from adults.
Taiga Biotechnologies are now in the process of setting up first-in-human clinical trials with the blood stem cell expansion approaches described in the article. The clinical applications for expanded human blood stem cells vary from inborn immunodeficiency conditions, like SCID and sickle cell anemia, to metabolic conditions, like Hurler's disease or Gaucher syndrome.
Autoimmune diseases that could be affected include severe multiple sclerosis and lupus. And the types of cancer that could be treated as a result of this research include leukemia, lymphoma, myeloma and other types of solid tumors.
The article is published in PLOS ONE. (ANI)
Link:
Scientists' new approach can provide better treatment for cancer
Posted: September 3, 2014 at 3:45 am
PUBLIC RELEASE DATE:
2-Sep-2014
Contact: Karen Richardson krchrdsn@wakehealth.edu 336-716-4453 Wake Forest Baptist Medical Center
Winston-Salem, N.C. Sept. 2, 2014 What if repairing large segments of damaged muscle tissue was as simple as mobilizing the body's stem cells to the site of the injury? New research in mice and rats, conducted at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine, suggests that "in body" regeneration of muscle tissue might be possible by harnessing the body's natural healing powers.
Reporting online ahead of print in the journal Acta Biomaterialia, the research team demonstrated the ability to recruit stem cells that can form muscle tissue to a small piece of biomaterial, or scaffold that had been implanted in the animals' leg muscle. The secret to success was using proteins involved in cell communication and muscle formation to mobilize the cells.
"Working to leverage the body's own regenerative properties, we designed a muscle-specific scaffolding system that can actively participate in functional tissue regeneration," said Sang Jin Lee, Ph.D., assistant professor of regenerative medicine and senior author. "This is a proof-of-concept study that we hope can one day be applied to human patients."
The current treatment for restoring function when large segments of muscle are injured or removed during tumor surgery is to surgically move a segment of muscle from one part of the body to another. Of course, this reduces function at the donor site.
Several scientific teams are currently working to engineer replacement muscle in the lab by taking small biopsies of muscle tissue, expanding the cells in the lab, and placing them on scaffolds for later implantation. This approach requires a biopsy and the challenge of standardizing the cells.
"Our aim was to bypass the challenges of both of these techniques and to demonstrate the mobilization of muscle cells to a target-specific site for muscle regeneration," said Lee.
Most tissues in the body contain tissue-specific stem cells that are believed to be the "regenerative machinery" responsible for tissue maintenance. It was these cells, known as satellite or progenitor cells, that the scientists wanted to mobilize.
Read more here:
Research in rodents suggests potential for 'in body' muscle regeneration
Posted: September 3, 2014 at 3:45 am
PUBLIC RELEASE DATE:
2-Sep-2014
Contact: John P. Wikswo john.wikswo@vanderbilt.edu 615-343-4124 Society for Experimental Biology and Medicine
The Annual Thematic issue of Experimental Biology and Medicine that appears in September 2014 is devoted to "The biology and medicine of microphysiological systems" and describes the work of scientists participating in the Microphysiological Systems Program directed by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and funded in part by the NIH Common Fund. The Defense Advanced Research Projects Agency (DARPA) and the Food and Drug Administration (FDA) are collaborating with the NIH in the program. Fourteen of the research teams supported by the program have contributed papers and represent more than 20 institutions, including Baylor College of Medicine, Columbia University, Cornell University, Duke University, Johns Hopkins University, Massachusetts General Hospital and Harvard Medical School, the Massachusetts Institute of Technology, Northwestern University, Nortis, Inc., the University of California, Irvine, the University of Central Florida, the University of Pennsylvania, the University of Pittsburgh, the University of Texas Medical Branch, and Vanderbilt University.
Dr. John P. Wikswo, founding Director of the Vanderbilt Institute for Integrative Biosystems Research and Education and Editor of the Thematic Issue, explains in his introductory review that microphysiological systems (MPS) often called "organs-on-chips" are interacting sets of constructs of human cells. Each construct is designed to recapitulate the structure and function of a human organ or organ region, and when connected in an MPS, they may provide in vitro models with great physiological accuracy for studying cell-cell, drug-cell, drug-drug, and organ-drug interactions. The papers in the Thematic Issue describe the ongoing development of MPS as in vitro models for bone and cartilage, brain, gastrointestinal tract, lung, liver, microvasculature, reproductive tract, skeletal muscle, and skin, as well as the interconnection of organs-on-chips to support physiologically based pharmacokinetics and drug discovery and screening, and the microscale technologies that regulate stem cell differentiation. Wikswo notes that the initial motivation for creating MPS was to increase the efficiency and human relevance of pharmaceutical development and testing. Obvious applications of the technology include studies of the effect of environmental toxins on humans, identification, characterization, and neutralization of chemical and biological weapons, controlled studies of the microbiome and infectious disease that cannot be conducted in humans, controlled differentiation of induced pluripotent stem cells into specific adult cellular phenotypes, and studies of the dynamics of metabolism and signaling within and between human organs.
In his commentary for the Thematic Issue, Dr. William Slikker Jr., Director of the FDA's National Center for Toxicological Research, writes "The goal [is] to accomplish this human-on-a-chip capability in a decade a feat somewhat equivalent to the moon shot of the 1960s and, like landing man on the moon, simulating a human being from a physiological/toxicological perspective may indeed be possible. But even if ultimately it is not, a great deal of fundamental biology and physiology will be elucidated along the way, much to the benefit of our understanding of human health and disease processes."
Dr. D. Lansing Taylor, Director of the University of Pittsburgh Drug Discovery Institute, says "The Thematic Issue brings together the leaders of the field of Human-on-a-Chip to discuss the early successes, great potential and continuing challenges of this emerging field. For complete success, we must integrate advances in multiple technical areas, including microfluidics, stem cell biology, 3D microstructures/matrices, multi-cell engineering, universal blood substitutes, and a variety of biological detection technologies, database tools, and computational modeling for both single and a combination of organ systems. Success will be transformative for basic biology, physiology, pharmacology, toxicology and medicine, as well as the new field of quantitative systems pharmacology, where iterative experimentation and computational modeling of disease models and pharmacodynamics and pharmacokinetics are central. The focus is to create physiologically relevant, robust, reproducible and cost-effective tools for the scientific community."
Dr. Danilo A. Tagle, NIH NCATS Associate Director for Special Initiatives, adds "This special issue highlights the exciting and rapid progress towards development of MPS for drug safety and efficacy testing. Much progress has been achieved in the two years of the program, and these articles describe the efforts by an outstanding group of investigators towards realizing the goal of fully integrated 10 organ systems. There are tremendous scientific opportunities and discoveries that could be had in the future utility of these tissues/organs on chips."
Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, agrees. "We are proud to publish this Thematic Issue dedicated to "The biology and medicine of microphysiological systems." Dr. John Wikswo is to be congratulated for assembling an exceptional group of researchers who are leaders in the field of MPS and the many uses of this exciting technology. MPS has the potential to revolutionize experimental biology and medicine. Because of the great importance and promise of organs-on-chips and MPS technology, it has now become a major area of emphasis for the Systems Biology category of Experimental Biology and Medicine."
###
See original here:
Microphysiological systems will revolutionize experimental biology and medicine
Posted: September 3, 2014 at 3:41 am
The treatment involves injecting up to 20 million stem cells into patients' brains. It was tested on patients at Glasgow's Southern General Hospital in 2012.
The Surrey-based company said it would work at 10 sites across the UK, including the Southern General, on a Phase II efficacy study of the ReN001 treatment involving 41 patients.
Loading article content
The treatment is designed to deliver a meaningful improvement in upper limb function in disabled stroke patients.
In May, the company said data from a long-term follow- up involving 11 patients included in a Phase I safety study of ReN001 at the Glasgow hospital observed sustained reductions in neurological impairment and spasticity in most patients. No cell-related or immunological adverse events were reported .
Yesterday, Reneuron said it has also started a Phase I safety study at Ninewells Hospital in Dundee of its ReN009 therapy for people with lower limb ischaemia. It will involve nine patients.
Reneuron says the disease is common in patients with diabetes and can lead to amputation of the limb.
Follow this link:
Reneuron tests stem cell stroke treatment
Posted: September 3, 2014 at 2:54 am
Looking for help with HPV Infection in Portsmouth? Listed below are doctors and medical centers in and near Portsmouth New Hampshire.
If you are not looking for help with HPV Infection, check out the popular HPV Infection info on the right navigation area of the page. On the HPV Infection pages we include website links so you can check out HPV Infection online.
Are you searching for information about HPV Infection? Have you or someone you know been diagnosed with HPV Infection? Have you considered Stem Cell treatments for HPV Infection? Welcome to the stem cell center service for the state of KY! Many diseases and illnesses don't have to be as treacherous as once thought. There are potential cures and treatments available that are quite effective and very hopeful for HPV Infection If you are ready to consider adult stem cell treatment and adult stem cell therapy as an alternative for your medical disorder HPV Infection, then you are at the right place. Here at alternativetreatmentsfor.com we specialize in providing effective stem cells for HPV Infection in or near Portsmouth, KY 3801. For immediate, free, and confidential assistance, download or .pdf file and call our helpline NOW!
Are you searching for a stem cell? Have you or someone you know been diagnosed with HPV Infection ? Welcome to the stem cell center service for the state of New Hampshire! Many diseases and illnesses are more treatable than most people once thought. There are many potential cures - stem cells and treatments available that have proven to be quite effective and very hopeful for HPV Infection
If you are open to the idea of adult stem cell treatment and adult stem cell therapy as an alternative method of treatment for your medical disorder HPV Infection, then you have found the right place. Here at naturalcurefor.com we specialize in helping people heal by providing effective and stem cells for HPV Infection in or near Portsmouth, New Hampshire 3801. For immediate, free, and confidential assistance, download our .pdf file and call our helpline NOW!
We have successfully helped many people in New Hampshire. We can help you attain real, effective, stem cells and alternative treatments for HPV Infection. Health improvements after our natural method of treatments have been used have shown terrific results in a very high percentage of cases. Every human being deserves to have good health and that is our desire to sincerely provide a network of resources available to help you or your loved one achieve better health. Don't let another day or week go by. Don't think that the pain or the HPV Infection you or a loved one have endured cannot be ended or put on a better more natural healing path to good health. Don't give up hope. We can help you recover, but you have to take the first step by contacting us now!
Portsmouth, New Hampshire - Stem cell for HPV Infection - We Can Provide Some Tremendous Hope if You Are Willing to Consider Adult Stem Cell Therapy and Treatments as Your Path Back To Good Health
Treating HPV Infection in a traditional medical manner is sometimes a long and grueling process that can offer less hope than you deserve. Additionally, many traditional medical treatments are riddled with drugs and medications that can sometimes cause even more harm to other parts of the body. Further risks of medication mixups, allergies, destruction of the immune system and the constant level of additional medical treatments that may be required, can sometimes weigh heavily on a patient and their chances of regaining a healthful way of life. Recovery can become difficult or almost impossible in some cases.
We offer an alternative treatment or a more stem cell process that centers around the idea of using your own adult stem cells as the basis of this natural treatment. In some areas of the country, traditional medicine and medical practices may not have acknowledged the benefits that stem cell treatments can bring to the healing process. Stem cell treatments may not be a standard course of medical treatment quite yet, but that may be a result of other political and/or profit motives. But rest assured that is all changing and changing quite rapidly as more and more success and overwhelming evidence indicates that adult stem cell therapy is a very successful and viable treatment process for HPV Infection.
Stem cell treatment is extremely effective and very safe. It is also very natural, ethical and a very effective way in assisting the body to heal naturally and wholesomely. It embodies the very idea of "healing" rather than simply medicating a symptom. The main idea of how adult stem cell treatments work are as follows...
Read the original here:
Stem cell therapy for HPV Infection in Portsmouth New ...
